Actively Recruiting
Impact of Antiglycemic & Immunosuppressive Therapies on NETosis in Diabetes & Kidney Disease (NETs - Neutrophil Traps)
Led by Western Galilee Hospital-Nahariya · Updated on 2025-02-12
70
Participants Needed
1
Research Sites
398 weeks
Total Duration
On this page
AI-Summary
What this Trial Is About
This study aims to investigate whether new glucose-lowering medications, such as SGLT2 inhibitors (e.g., Forxiga/Jardiance) and GLP-1 receptor agonists (e.g., Ozempic), can reduce NETosis in diabetic patients, thereby mitigating secondary complications such as cardiovascular disease and kidney damage. By targeting dysregulated NET formation, the study seeks to establish a link between reduced NETosis and improved clinical outcomes in diabetes. Additionally, the study will evaluate the effects of immunosuppressive therapies on NETosis in patients with immune-mediated kidney diseases, such as ANCA-associated vasculitis. By correlating NETosis activity with disease progression and treatment response, this research will assess whether reducing NETosis contributes to better management of inflammation and secondary morbidity in these conditions. Through these evaluations, the study aims to identify potential therapeutic strategies to improve outcomes in both diabetic and chronic kidney disease populations.
CONDITIONS
Official Title
Impact of Antiglycemic & Immunosuppressive Therapies on NETosis in Diabetes & Kidney Disease (NETs - Neutrophil Traps)
Who Can Participate
Eligibility Criteria
You may qualify if you...
- Diabetic patients aged 18 years or older (men and women)
- Patients who have not previously received SGLT2 inhibitors or GLP-1 receptor agonists
- Chronic kidney disease patients with various causes
- Patients with immune-mediated kidney disease, such as ANCA-associated vasculitis, for evaluation of immunosuppressive therapy effects
You will not qualify if you...
- Patients with acute infections
- Patients with hematologic or oncologic diseases
- Patients positive for HIV
- Patients positive for Hepatitis B or C
AI-Screening
AI-Powered Screening
Complete this quick 3-step screening to check your eligibility
Trial Site Locations
Total: 1 location
1
Galilee Medical Center
Nahariya, Israel, 2210001
Actively Recruiting
Research Team
E
Etty Kruzel-Davila, MD
CONTACT
O
Olga Vdovich, MD
CONTACT
How is the study designed?
Study Type
OBSERVATIONAL
Masking
N/A
Allocation
N/A
Model
N/A
Primary Purpose
N/A
Number of Arms
3
Not the Right Trial for You?
Explore thousands of other clinical trials that might be a better match.
Sign up to get personalized trial recommendations delivered to your inbox.
Already have an account? Log in here